The combination of technologies will enhance their shared biopharmaceutical partners’ ability to identify patients most likely to respond to drugs in clinical trials.
The combination of technologies will enhance their shared biopharmaceutical partners’ ability to identify patients most likely to respond to drugs in clinical trials.